{"id":396161,"date":"2020-12-09T07:03:49","date_gmt":"2020-12-09T12:03:49","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=396161"},"modified":"2020-12-09T07:03:49","modified_gmt":"2020-12-09T12:03:49","slug":"valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/","title":{"rendered":"Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>\n          <b>Commercial launch to impact first half 2021 revenue<\/b>\n        <\/li>\n<li>\n          <b><br \/>\n            <span class=\"xn-money\">$30 million<\/span> forecasted annual peak sales <\/b>\n        <\/li>\n<li>\n          <b>8 years of proven in-market safety Internationally<\/b>\n        <\/li>\n<li>\n          <b>Low molecular weight heparin increasingly used to prevent COVID-19 driven complications<\/b>\n        <\/li>\n<\/ul>\n<p>\n        <span class=\"xn-location\">MONTREAL<\/span>, <span class=\"xn-chron\">Dec. 9, 2020<\/span> \/PRNewswire\/ &#8211;\u00a0<b><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3007118-1&amp;h=2034941868&amp;u=https%3A%2F%2Fwww.valeopharma.com%2F&amp;a=Valeo+Pharma+Inc\" rel=\"nofollow noopener noreferrer\">Valeo Pharma Inc<\/a><\/b>. (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) (&#8220;<b>Valeo<\/b>&#8221; or the &#8220;<b>Company<\/b>&#8220;), a Canadian pharmaceutical company,\u00a0 announced today that Health Canada has issued a Notice of Compliance for Redesca and Redesca HP low molecular weight heparin (&#8220;LMWH&#8221;) biosimilars. \u00a0<\/p>\n<p>&#8220;The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly\u00a0 being adopted across the country and is expected to help provide significant savings to provincial healthcare plans&#8221;, said <span class=\"xn-person\">Steve Saviuk<\/span>, President and CEO. &#8220;With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives&#8221;.<\/p>\n<p>&#8220;The Canadian LMWH market is in excess of <span class=\"xn-money\">$200 Million<\/span> annually and our complete product line and differentiating clinical package will be a beneficial factor helping to rapidly secure market share in provinces across <span class=\"xn-location\">Canada<\/span>,&#8221; added Mr. Saviuk.<\/p>\n<p>In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWH are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization&#8217;s (&#8220;WHO&#8221;) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.<\/p>\n<p>\n        <b>Digital Investor Awareness Program<\/b>\n      <\/p>\n<p>The Company also announces that it has launched a 12-month digital investor awareness program \u00a0through AGORACOM, a multifaceted digital platform operated by AGORA Internet Services Corp. (&#8220;AGORA&#8221;),\u00a0 in order to enhance information availability for current and future stakeholders. The Company has agreed\u00a0 to remunerate AGORA \u00a0$75,000 plus taxes for the above mentioned services. A first service payment of <span class=\"xn-money\">$15,000<\/span> was made on\u00a0 <span class=\"xn-chron\">December 7, 2020<\/span> with the remaining balance split equally and due on each of <span class=\"xn-chron\">February 27, 2021<\/span>, <span class=\"xn-chron\">May 27, 2021<\/span>, <span class=\"xn-chron\">August 27, 2021<\/span>, and <span class=\"xn-chron\">December 31, 2021<\/span><\/p>\n<p>Payment will be made through the issuance of the Company&#8217;s common shares with the number of common shares to be issued determined by using the closing price on each date above. Common shares issued to AGORA under this agreement will be subject to a 4-month hold period. <\/p>\n<p>\n        <b>About Redesca<\/b>\n      <\/p>\n<p>Redesca is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in <span class=\"xn-location\">Europe<\/span> alone. <\/p>\n<p>\n        <b>About Valeo Pharma<\/b>\n      <\/p>\n<p>Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in <span class=\"xn-location\">Canada<\/span> with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in <span class=\"xn-location\">Kirkland, Quebec<\/span>, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit <b><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3007118-1&amp;h=249794216&amp;u=http%3A%2F%2Fwww.valeopharma.com%2F&amp;a=www.valeopharma.com\" rel=\"nofollow noopener noreferrer\">www.valeopharma.com<\/a><\/b>and follow us on <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3007118-1&amp;h=812973310&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fvaleo-pharma&amp;a=LinkedIn\" rel=\"nofollow noopener noreferrer\"><b>LinkedIn<\/b><\/a>\u00a0and <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3007118-1&amp;h=927182015&amp;u=https%3A%2F%2Ftwitter.com%2Fvaleo_pharma%3Flang%3Den&amp;a=Twitter\" rel=\"nofollow noopener noreferrer\"><b>Twitter<\/b><\/a><b>.<\/b><\/p>\n<p>\n        <b>Forward Looking Statements<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements about Valeo&#8217;s objectives, strategies and businesses that involve risks and uncertainties. These statements are &#8220;forward-looking&#8221; because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.<\/p>\n<p>NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO18021&amp;sd=2020-12-09\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp-301189205.html\">http:\/\/www.prnewswire.com\/news-releases\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp-301189205.html<\/a><\/p>\n<p>SOURCE  Valeo Pharma Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=MO18021&amp;Transmission_Id=202012090700PR_NEWS_USPR_____MO18021&amp;DateId=20201209\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Commercial launch to impact first half 2021 revenue $30 million forecasted annual peak sales 8 years of proven in-market safety Internationally Low molecular weight heparin increasingly used to prevent COVID-19 driven complications MONTREAL, Dec. 9, 2020 \/PRNewswire\/ &#8211;\u00a0Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) (&#8220;Valeo&#8221; or the &#8220;Company&#8220;), a Canadian pharmaceutical company,\u00a0 announced today that Health Canada has issued a Notice of Compliance for Redesca and Redesca HP low molecular weight heparin (&#8220;LMWH&#8221;) biosimilars. \u00a0 &#8220;The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly\u00a0 being adopted across the country and is expected to help provide significant savings to provincial &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-396161","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Commercial launch to impact first half 2021 revenue $30 million forecasted annual peak sales 8 years of proven in-market safety Internationally Low molecular weight heparin increasingly used to prevent COVID-19 driven complications MONTREAL, Dec. 9, 2020 \/PRNewswire\/ &#8211;\u00a0Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) (&#8220;Valeo&#8221; or the &#8220;Company&#8220;), a Canadian pharmaceutical company,\u00a0 announced today that Health Canada has issued a Notice of Compliance for Redesca and Redesca HP low molecular weight heparin (&#8220;LMWH&#8221;) biosimilars. \u00a0 &#8220;The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly\u00a0 being adopted across the country and is expected to help provide significant savings to provincial &hellip; Continue reading &quot;Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-09T12:03:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO18021&amp;sd=2020-12-09\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122\",\"datePublished\":\"2020-12-09T12:03:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\\\/\"},\"wordCount\":635,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=MO18021&amp;sd=2020-12-09\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\\\/\",\"name\":\"Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=MO18021&amp;sd=2020-12-09\",\"datePublished\":\"2020-12-09T12:03:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=MO18021&amp;sd=2020-12-09\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=MO18021&amp;sd=2020-12-09\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/","og_locale":"en_US","og_type":"article","og_title":"Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122 - Market Newsdesk","og_description":"PR Newswire Commercial launch to impact first half 2021 revenue $30 million forecasted annual peak sales 8 years of proven in-market safety Internationally Low molecular weight heparin increasingly used to prevent COVID-19 driven complications MONTREAL, Dec. 9, 2020 \/PRNewswire\/ &#8211;\u00a0Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) (&#8220;Valeo&#8221; or the &#8220;Company&#8220;), a Canadian pharmaceutical company,\u00a0 announced today that Health Canada has issued a Notice of Compliance for Redesca and Redesca HP low molecular weight heparin (&#8220;LMWH&#8221;) biosimilars. \u00a0 &#8220;The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly\u00a0 being adopted across the country and is expected to help provide significant savings to provincial &hellip; Continue reading \"Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-09T12:03:49+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO18021&amp;sd=2020-12-09","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122","datePublished":"2020-12-09T12:03:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/"},"wordCount":635,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO18021&amp;sd=2020-12-09","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/","name":"Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO18021&amp;sd=2020-12-09","datePublished":"2020-12-09T12:03:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO18021&amp;sd=2020-12-09","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO18021&amp;sd=2020-12-09"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Valeo Pharma Announces Health Canada Approval for Redesca\u2122 and Redesca Hp\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=396161"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396161\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=396161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=396161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=396161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}